Treatment of Uremic Pruritus With PA101B

ClinicalTrials.gov ID: NCT02696499

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02696499. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Treatment of Uremic Pruritus With Inhaled PA101B in Patients With End-Stage Renal Disease Requiring Hemodialysis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2, proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring hemodialysis. The purpose of the study is to determine the efficacy and safety profile of PA101B delivered via eFlow high efficiency nebulizer in patients with uremic pruritus who are symptomatic despite using standard treatments.

Study identification

NCT ID: NCT02696499
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Patara Pharma; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Uremic Pruritus

Interventions

PA101B Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2016 (Type not available)
Primary completion: Aug 2016 (Actual)
Completion: Dec 2016 (Actual)
Last update posted: Apr 20, 2018

2016

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Arizona Kidney Disease and Hypertension Center	Phoenix	Arizona	85012	—
US Renal Care	Pine Bluff	Arkansas	71603	—
Valley Renal Medical Group	Northridge	California	91324	—
North America Research Institute	San Dimas	California	91773	—
Pines Clinical Research, Inc.	Pembroke Pines	Florida	33028	—
Genesis Clinical Research	Tampa	Florida	33614	—
Boise Kidney and Hypertension Institute	Meridian	Idaho	83642	—
Fresenius Medical Care of Evergreen Park	Evergreen Park	Illinois	60805	—
Renal Medicine Associates	Albuquerque	New Mexico	87109	—
US Renal Care	Gallup	New Mexico	87313	—
Ridgewood Dialysis Center	Ridgewood	New York	11385	—
Brookview Hills Research Associates LLC	Winston-Salem	North Carolina	27103	—
Southeast Renal Research Institute	Chattanooga	Tennessee	37408	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02696499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 20, 2018 · Synced Nov 14, 2026